Brian Druker

Top papers

• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

  Brian Druker, Moshe Talpaz, Debra Resta, et al.·2001·New England Journal of Medicine
  ↗ 5,231OA
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

  George D. Demetri, Margaret von Mehren, Charles D. Blanke, et al.·2002·New England Journal of Medicine
  ↗ 4,375OA
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  Brian Druker, Shu Tamura, Elisabeth Buchdunger, et al.·1996·Nature Medicine
  ↗ 3,652
• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  Stephen G. O’Brien, François Guilhot, Richard A. Larson, et al.·2003·New England Journal of Medicine
  ↗ 3,557OA
• Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

  Brian Druker, François Guilhot, Stephen G. O’Brien, et al.·2006·New England Journal of Medicine
  ↗ 3,470OA
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

  Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian, et al.·2001·New England Journal of Medicine
  ↗ 2,717OA
• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

  Michael C. Heinrich, Christopher L. Corless, George D. Demetri, et al.·2003·Journal of Clinical Oncology
  ↗ 2,291
• Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

  Heikki Joensuu, Peter Roberts‎, Maarit Sarlomo‐Rikala, et al.·2001·New England Journal of Medicine
  ↗ 2,055OA
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

  Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus, et al.·2002·New England Journal of Medicine
  ↗ 2,027OA
• Functional genomic landscape of acute myeloid leukaemia

  Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly, et al.·2018·Nature
  ↗ 1,431OA
• Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

  Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law, et al.·2000·Journal of Pharmacology and Experimental Therapeutics
  ↗ 1,280
• The development of imatinib as a therapeutic agent for chronic myeloid leukemia

  Michael W. Deininger, Elisabeth Buchdunger, Brian Druker·2004·Blood
  ↗ 1,242